Janux Therapeutics (JANX) Competitors $14.52 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$14.51 -0.01 (-0.07%) As of 05/22/2026 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX vs. ERAS, TWST, RCUS, TNGX, and DNLIShould you buy Janux Therapeutics stock or one of its competitors? MarketBeat compares Janux Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Janux Therapeutics include Erasca (ERAS), Twist Bioscience (TWST), Arcus Biosciences (RCUS), Tango Therapeutics (TNGX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. JANX vs. ERASJANX vs. TWSTJANX vs. RCUSJANX vs. TNGXJANX vs. DNLIHow does Janux Therapeutics compare to Erasca?Erasca (NASDAQ:ERAS) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation. Do analysts prefer ERAS or JANX? Erasca presently has a consensus price target of $18.75, indicating a potential upside of 66.81%. Janux Therapeutics has a consensus price target of $45.85, indicating a potential upside of 215.74%. Given Janux Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 2 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50Janux Therapeutics 2 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.60 Is ERAS or JANX more profitable? Janux Therapeutics' return on equity of -12.93% beat Erasca's return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -35.31% -29.49% Janux Therapeutics N/A -12.93%-12.23% Does the media favor ERAS or JANX? In the previous week, Erasca had 7 more articles in the media than Janux Therapeutics. MarketBeat recorded 7 mentions for Erasca and 0 mentions for Janux Therapeutics. Erasca's average media sentiment score of 0.00 equaled Janux Therapeutics'average media sentiment score. Company Overall Sentiment Erasca Neutral Janux Therapeutics Neutral Which has more risk & volatility, ERAS or JANX? Erasca has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.58, meaning that its share price is 158% more volatile than the broader market. Which has preferable earnings & valuation, ERAS or JANX? Janux Therapeutics has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$124.55M-$0.93N/AJanux Therapeutics$10M88.54-$113.62M-$1.84N/A Do institutionals & insiders have more ownership in ERAS or JANX? 67.8% of Erasca shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryJanux Therapeutics beats Erasca on 11 of the 14 factors compared between the two stocks.How does Janux Therapeutics compare to Twist Bioscience?Janux Therapeutics (NASDAQ:JANX) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Do analysts recommend JANX or TWST? Janux Therapeutics currently has a consensus target price of $45.85, suggesting a potential upside of 215.74%. Twist Bioscience has a consensus target price of $58.00, suggesting a potential downside of 4.24%. Given Janux Therapeutics' higher possible upside, equities research analysts clearly believe Janux Therapeutics is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 2 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.60Twist Bioscience 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk and volatility, JANX or TWST? Janux Therapeutics has a beta of 2.58, indicating that its share price is 158% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market. Which has higher earnings & valuation, JANX or TWST? Twist Bioscience has higher revenue and earnings than Janux Therapeutics. Twist Bioscience is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10M88.54-$113.62M-$1.84N/ATwist Bioscience$376.57M10.02-$77.67M-$1.33N/A Is JANX or TWST more profitable? Janux Therapeutics has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Janux Therapeutics' return on equity of -12.93% beat Twist Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -12.93% -12.23% Twist Bioscience -19.85%-26.73%-19.15% Does the media prefer JANX or TWST? In the previous week, Twist Bioscience had 5 more articles in the media than Janux Therapeutics. MarketBeat recorded 5 mentions for Twist Bioscience and 0 mentions for Janux Therapeutics. Twist Bioscience's average media sentiment score of 0.89 beat Janux Therapeutics' score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Overall Sentiment Janux Therapeutics Neutral Twist Bioscience Positive Do insiders & institutionals hold more shares of JANX or TWST? 75.4% of Janux Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Twist Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryJanux Therapeutics beats Twist Bioscience on 11 of the 17 factors compared between the two stocks.How does Janux Therapeutics compare to Arcus Biosciences?Arcus Biosciences (NYSE:RCUS) and Janux Therapeutics (NASDAQ:JANX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Do analysts recommend RCUS or JANX? Arcus Biosciences currently has a consensus target price of $33.89, indicating a potential upside of 44.36%. Janux Therapeutics has a consensus target price of $45.85, indicating a potential upside of 215.74%. Given Janux Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Janux Therapeutics is more favorable than Arcus Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 1 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.55Janux Therapeutics 2 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more volatility and risk, RCUS or JANX? Arcus Biosciences has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.58, indicating that its stock price is 158% more volatile than the broader market. Which has preferable valuation and earnings, RCUS or JANX? Janux Therapeutics has lower revenue, but higher earnings than Arcus Biosciences. Janux Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$247M11.95-$353M-$3.18N/AJanux Therapeutics$10M88.54-$113.62M-$1.84N/A Is RCUS or JANX more profitable? Janux Therapeutics has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Janux Therapeutics' return on equity of -12.93% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-156.36% -68.97% -35.27% Janux Therapeutics N/A -12.93%-12.23% Does the media prefer RCUS or JANX? In the previous week, Arcus Biosciences had 1 more articles in the media than Janux Therapeutics. MarketBeat recorded 1 mentions for Arcus Biosciences and 0 mentions for Janux Therapeutics. Arcus Biosciences' average media sentiment score of 1.87 beat Janux Therapeutics' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Overall Sentiment Arcus Biosciences Very Positive Janux Therapeutics Neutral Do institutionals and insiders have more ownership in RCUS or JANX? 92.9% of Arcus Biosciences shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 9.6% of Arcus Biosciences shares are held by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryJanux Therapeutics beats Arcus Biosciences on 11 of the 17 factors compared between the two stocks.How does Janux Therapeutics compare to Tango Therapeutics?Janux Therapeutics (NASDAQ:JANX) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the media prefer JANX or TNGX? In the previous week, Tango Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 2 mentions for Tango Therapeutics and 0 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.00 beat Tango Therapeutics' score of -0.40 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Janux Therapeutics Neutral Tango Therapeutics Neutral Is JANX or TNGX more profitable? Janux Therapeutics has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. Janux Therapeutics' return on equity of -12.93% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -12.93% -12.23% Tango Therapeutics -151.15%-41.54%-33.44% Do analysts rate JANX or TNGX? Janux Therapeutics currently has a consensus price target of $45.85, indicating a potential upside of 215.74%. Tango Therapeutics has a consensus price target of $32.27, indicating a potential upside of 59.45%. Given Janux Therapeutics' higher possible upside, equities research analysts plainly believe Janux Therapeutics is more favorable than Tango Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 2 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.60Tango Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.64 Do institutionals & insiders believe in JANX or TNGX? 75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, JANX or TNGX? Janux Therapeutics has a beta of 2.58, suggesting that its share price is 158% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Which has preferable earnings and valuation, JANX or TNGX? Tango Therapeutics has higher revenue and earnings than Janux Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Janux Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10M88.54-$113.62M-$1.84N/ATango Therapeutics$62.38M46.93-$101.59M-$0.83N/A SummaryJanux Therapeutics beats Tango Therapeutics on 10 of the 17 factors compared between the two stocks.How does Janux Therapeutics compare to Denali Therapeutics?Janux Therapeutics (NASDAQ:JANX) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment. Which has more volatility and risk, JANX or DNLI? Janux Therapeutics has a beta of 2.58, suggesting that its share price is 158% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Which has stronger earnings & valuation, JANX or DNLI? Janux Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanux Therapeutics$10M88.54-$113.62M-$1.84N/ADenali Therapeutics$330.53M8.95-$512.54M-$2.88N/A Does the media prefer JANX or DNLI? In the previous week, Denali Therapeutics had 2 more articles in the media than Janux Therapeutics. MarketBeat recorded 2 mentions for Denali Therapeutics and 0 mentions for Janux Therapeutics. Janux Therapeutics' average media sentiment score of 0.00 beat Denali Therapeutics' score of -0.33 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Janux Therapeutics Neutral Denali Therapeutics Neutral Is JANX or DNLI more profitable? Janux Therapeutics' return on equity of -12.93% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Janux TherapeuticsN/A -12.93% -12.23% Denali Therapeutics N/A -52.20%-43.86% Do insiders & institutionals hold more shares of JANX or DNLI? 75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate JANX or DNLI? Janux Therapeutics currently has a consensus target price of $45.85, suggesting a potential upside of 215.74%. Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 83.74%. Given Janux Therapeutics' higher possible upside, equities research analysts plainly believe Janux Therapeutics is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Janux Therapeutics 2 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.60Denali Therapeutics 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.87 SummaryJanux Therapeutics beats Denali Therapeutics on 8 of the 15 factors compared between the two stocks. Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JANX vs. The Competition ExportMetricJanux TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$885.49M$3.37B$6.45B$12.34BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-7.8910.3417.9322.89Price / Sales88.54323.98553.9286.28Price / CashN/A125.1743.4956.67Price / Book0.947.0910.377.14Net Income-$113.62M$24.45M$3.57B$335.98M7 Day Performance3.49%5.45%6.01%3.56%1 Month Performance-3.26%2.43%3.52%2.54%1 Year Performance-42.43%62.98%34.13%35.05% Janux Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JANXJanux Therapeutics2.5238 of 5 stars$14.52flat$45.85+215.7%-42.4%$885.49M$10MN/A30ERASErasca3.2219 of 5 stars$10.27+0.4%$18.75+82.6%+821.3%$3.18BN/AN/A120Gap UpTWSTTwist Bioscience1.7264 of 5 stars$49.79+1.3%$56.57+13.6%+114.3%$3.06B$376.57MN/A990Analyst ForecastGap UpRCUSArcus Biosciences3.6528 of 5 stars$23.43-1.5%$33.89+44.7%+159.5%$2.99B$247MN/A500TNGXTango Therapeutics2.4414 of 5 stars$20.63+0.3%$32.27+56.4%+1,000.0%$2.97B$56.99MN/A90Gap Up Related Companies and Tools Related Companies ERAS Competitors TWST Competitors RCUS Competitors TNGX Competitors DNLI Competitors ALMS Competitors GMTX Competitors BEAM Competitors DYN Competitors MOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JANX) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
